摘要:
The present invention relates to the regulation of the activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity. The invention further relates to methods of screening for agonists or antagonists of NET in order to identify new pro-angiogenic or anti-angiogenic compounds and to therapeutic uses of these compounds. The invention also relates to transgenic animals bearing mutations in NET gene.
摘要:
A polypeptide containing epitope of the amino acid sequence shown in SEQ ID NO:3 is provided, which is selected from the amino acid sequence of SEQ ID NO:3 and amino acids at 16-32 positions, amino acids at 1-30 positions, amino acids at 50-80 positions and amino acids at 17-200 positions of the amino acid sequence shown in SEQ ID NO:3. The nucleic acid molecule encoding the polypeptide, recombinant vectors and host cells comprising the nucleic acid molecule are also provided. The polypeptide and the nucleic acid molecule encoding it can be used for preparing reagents, kits or devices for diagnosing the diseases characterized by EECP expression and pharmaceutical compositions for preventing or treating the diseases characterized by EECP expression by increasing or inhibiting EECP expression and/or activity.
摘要翻译:提供了包含SEQ ID NO:3所示氨基酸序列的表位的多肽,其选自SEQ ID NO:3的氨基酸序列和16-32位的氨基酸,1-30位的氨基酸, SEQ ID NO:3所示氨基酸序列的50-80位氨基酸和17-200位氨基酸。 还提供了编码多肽的核酸分子,重组载体和包含核酸分子的宿主细胞。 编码它的多肽和核酸分子可用于制备用于诊断以EECP表达为特征的疾病的试剂,试剂盒或装置,以及用于通过增加或抑制EECP表达和/或活性来预防或治疗特征在于EECP表达的疾病的药物组合物 。
摘要:
Provided herein is a new class of cyclic lactadherin peptides (cLac) that mimic the natural phosphatidylserine (PS)-binding activity of the parent lactadherin protein. These cLacs are useful as small molecule indicators of early stage of apoptosis and of treatment efficacy evaluation.
摘要:
The present invention provides a method, a mobile terminal device and a system for determining a transmission power factor. During an uplink of data between a mobile terminal device and a base station via a code division multiple access (CDMA) system supported by automatic repeat request (ARQ) first transmission containing original data and re-transmissions of different order containing supplementary information are communicated. The i-th re-transmissions are based on the automatic repeat request (ARQ). The transmission power factor to be determined is operable with an i-th re-transmission. A first and a second error quantity are obtained from an evaluation of status information items received in accordance with the automatic repeat request (ARQ). The first error quantity and the second error quantity allow for deriving an i-th error ratio so as to calculate a transmission power correction factor.
摘要:
A polypeptide containing epitope of the amino acid sequence shown in SEQ ID NO:3 is provided, which is selected from the amino acid sequence of SEQ ID NO:3 and amino acids at 16-32 positions, amino acids at 1-30 positions, amino acids at 50-80 positions and amino acids at 17-200 positions of the amino acid sequence shown in SEQ ID NO:3. The nucleic acid molecule encoding the polypeptide, recombinant vectors and host cells comprising the nucleic acid molecule are also provided. The polypeptide and the nucleic acid molecule encoding it can be used for preparing reagents, kits or devices for diagnosing the diseases characterized by EECP expression and pharmaceutical compositions for preventing or treating the diseases characterized by EECP expression by increasing or inhibiting EECP expression and/or activity.
摘要翻译:提供了包含SEQ ID NO:3所示氨基酸序列的表位的多肽,其选自SEQ ID NO:3的氨基酸序列和16-32位的氨基酸,1-30位的氨基酸, SEQ ID NO:3所示氨基酸序列的50-80位氨基酸和17-200位氨基酸。 还提供了编码多肽的核酸分子,重组载体和包含核酸分子的宿主细胞。 编码它的多肽和核酸分子可用于制备用于诊断以EECP表达为特征的疾病的试剂,试剂盒或装置,以及用于通过增加或抑制EECP表达和/或活性来预防或治疗特征在于EECP表达的疾病的药物组合物 。